18 citations
,
October 2017 in “Drug Design Development and Therapy” DA-9401 helps protect rat testis from finasteride damage.
May 2024 in “News Digital Object Group”
November 2022 in “Orphanet Journal of Rare Diseases” Long-term use of androgens can help manage Hereditary Angioedema (HAE) but may cause serious side effects, so alternative treatments with fewer side effects are being considered.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
August 2011 in “Reactions Weekly” A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
JAK inhibitors show promise in treating moderate to severe alopecia areata.
January 1983 in “Side effects of drugs annual” Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.